Skip to main content
. 2020 Jan 3;13(1):8. doi: 10.3390/ph13010008

Table 1.

CBSIs in clinical trials and clinical use—non combretastatin A-4 analogues.

Drug Name Section Structural Features Stage in Clinical Trials and Disease Treated Company Developing Drug
ENMD1198 (74) Section 5.5 2-Methoxyestradiol derivative Phase I
refractory solid tumours		 Casi pharmaceuticals
(no data published in recent years)
CP461/OSI-461 (82) Section 5.11 Derivative of exisulind Phase II

  • Renal cell carcinoma

  • Prostate cancer

  • Chronic lymphocytic leukaemi

(Not yet marketed or in clinical use) 		Astellas
Tivantinib (86) Section 6.2.1 Heterocyclic fused ring system Phase II

  • Hepatocellular carcinoma (HCC)

  • Liver cancer

  • Non-small-cell lung carcinoma (NSCLC)

 Kyowa Hakko Kirin Co. Ltd.
(development discontinued in 2018 following multiple poor clinical trial outcomes)
Plinabulin (BAL27862) (75) Section 6.2.2 Contains benzimidazole and 3-amino oxadiazole moieties Phase III
stage IIIb/IV NSCLC (in combination with docetaxel)		 Beyond Spring Inc.
Lisavanbulin (BAL101553) (87) Section 6.2.3 Lysine prodrug of Plinabulin Phase I/IIa
advanced solid tumours, refractory to standard therapy		 Basilea Pharmaceutica
Crolibulin (78) Section 6.2.4 Chromene derivative Phase I/II Clinical trials
Anaplastic Thyroid Cancer		 Immune Pharmaceuticals Inc; National Cancer Institute (USA)
(clinical trial progression limited due to recruitment issues)